This is a preview of subscription content, log in via an institution to check access.
Literatur
Ni W, Shao X, Cai X et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PloS one. 2015;10:e0121257
Pomares X, Montón C, Bullich M et al. Clinical and safety outcomes of long-term azithromycin therapy in severe COPD beyond the first year of treatment. Chest. 2018;153:1125-33
Vogelmeier C, Buhl R, Burghuber O et al. Guideline for the Diagnosis and Treatment of COPD Patients - Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology. Pneumologie. 2018;72:253-308
Nationale Versorgungsleitlinie COPD, 2021. www.awmf.org; Stand 25.6.2021
Vermeersch K, Gabrovska M, Aumann J et al. Azithromycin during acute Chronic Obstructive Pulmonary Disease exacerbations requiring hospitalization (BACE). A Multicenter, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2019;200:857-68
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kohlhäufl, M. Azithromycin hoch- oder niedrigdosiert: COPD-Exazerbationsrate klinisch gleich. Pneumo News 13, 25–27 (2021). https://doi.org/10.1007/s15033-021-2788-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15033-021-2788-7